Stock Track | AbCellera Biologics Soars 18.63% as Q2 Revenue Triples, Beating Estimates

Stock Track

Aug 08, 2025

AbCellera Biologics (NASDAQ: ABCL) stock surged 18.63% in after-hours trading following the release of its second-quarter earnings report, which significantly exceeded analyst expectations. The Canadian biotechnology company, known for its AI-powered antibody discovery platform, demonstrated strong financial performance that has boosted investor confidence.

AbCellera reported quarterly revenue of $17.1 million, more than tripling the analyst consensus estimate of $6.12 million. This represents a substantial 133.29% increase compared to sales of $7.323 million in the same quarter of the previous year. The company's CEO attributed this impressive growth to higher licensing revenue, showcasing the increasing demand for AbCellera's innovative technologies.

While AbCellera still posted a net loss of $34.7 million, it was narrower than the $36.9 million loss reported in Q2 2024. The company's earnings per share (EPS) came in at a loss of $0.12, beating the analyst consensus estimate of a $0.15 loss. With over $750 million in available liquidity, AbCellera appears well-positioned to support its ongoing growth strategy. The market's enthusiastic response to these results underscores the potential investors see in AbCellera's unique approach to antibody discovery and development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1143382109"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143382109\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143382109?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 08:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143382109","market":"us","top_or_hot":-1,"title":"Stock Track | AbCellera Biologics Soars 18.63% as Q2 Revenue Triples, Beating Estimates","media":"Stock Track","content":"<p>AbCellera Biologics (NASDAQ: ABCL) stock surged 18.63% in after-hours trading following the release of its second-quarter earnings report, which significantly exceeded analyst expectations. The Canadian biotechnology company, known for its AI-powered antibody discovery platform, demonstrated strong financial performance that has boosted investor confidence.</p>\n\n<p>AbCellera reported quarterly revenue of $17.1 million, more than tripling the analyst consensus estimate of $6.12 million. This represents a substantial 133.29% increase compared to sales of $7.323 million in the same quarter of the previous year. The company's CEO attributed this impressive growth to higher licensing revenue, showcasing the increasing demand for AbCellera's innovative technologies.</p>\n\n<p>While AbCellera still posted a net loss of $34.7 million, it was narrower than the $36.9 million loss reported in Q2 2024. The company's earnings per share (EPS) came in at a loss of $0.12, beating the analyst consensus estimate of a $0.15 loss. With over $750 million in available liquidity, AbCellera appears well-positioned to support its ongoing growth strategy. The market's enthusiastic response to these results underscores the potential investors see in AbCellera's unique approach to antibody discovery and development.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AbCellera Biologics Soars 18.63% as Q2 Revenue Triples, Beating Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AbCellera Biologics Soars 18.63% as Q2 Revenue Triples, Beating Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-08 08:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AbCellera Biologics (NASDAQ: ABCL) stock surged 18.63% in after-hours trading following the release of its second-quarter earnings report, which significantly exceeded analyst expectations. The Canadian biotechnology company, known for its AI-powered antibody discovery platform, demonstrated strong financial performance that has boosted investor confidence.</p>\n\n<p>AbCellera reported quarterly revenue of $17.1 million, more than tripling the analyst consensus estimate of $6.12 million. This represents a substantial 133.29% increase compared to sales of $7.323 million in the same quarter of the previous year. The company's CEO attributed this impressive growth to higher licensing revenue, showcasing the increasing demand for AbCellera's innovative technologies.</p>\n\n<p>While AbCellera still posted a net loss of $34.7 million, it was narrower than the $36.9 million loss reported in Q2 2024. The company's earnings per share (EPS) came in at a loss of $0.12, beating the analyst consensus estimate of a $0.15 loss. With over $750 million in available liquidity, AbCellera appears well-positioned to support its ongoing growth strategy. The market's enthusiastic response to these results underscores the potential investors see in AbCellera's unique approach to antibody discovery and development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABCL","symbol_name":"AbCellera Biologics","start_time":0,"source_url":"","article_id":"1143382109","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143382109","pubTimestamp":1754612108,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AbCellera Biologics (NASDAQ: ABCL) stock surged 18.63% in after-hours trading following the release of its second-quarter earnings report, which significantly exceeded analyst expectations. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABCL":"AbCellera Biologics"},"translate_title":"个股追踪|AbCellera Biologics飙升18.63%Q2营收增长两倍超预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":1},"content_text":"AbCellera Biologics (NASDAQ: ABCL) stock surged 18.63% in after-hours trading following the release of its second-quarter earnings report, which significantly exceeded analyst expectations. The Canadian biotechnology company, known for its AI-powered antibody discovery platform, demonstrated strong financial performance that has boosted investor confidence.\nAbCellera reported quarterly revenue of $17.1 million, more than tripling the analyst consensus estimate of $6.12 million. This represents a substantial 133.29% increase compared to sales of $7.323 million in the same quarter of the previous year. The company's CEO attributed this impressive growth to higher licensing revenue, showcasing the increasing demand for AbCellera's innovative technologies.\nWhile AbCellera still posted a net loss of $34.7 million, it was narrower than the $36.9 million loss reported in Q2 2024. The company's earnings per share (EPS) came in at a loss of $0.12, beating the analyst consensus estimate of a $0.15 loss. With over $750 million in available liquidity, AbCellera appears well-positioned to support its ongoing growth strategy. The market's enthusiastic response to these results underscores the potential investors see in AbCellera's unique approach to antibody discovery and development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}